US 11,814,443 B2
Bi-specific fusion proteins
Ulrik Nielsen, Quincy, MA (US); Thomas Wickham, Groton, MA (US); Birgit Schoeberl, Cambridge, MA (US); Brian Harms, Roslindale, MA (US); Bryan Linggi, Richland, WA (US); Matthew Onsum, El Cerrito, CA (US); Byron DeLaBarre, Cambridge, MA (US); and Shaun M. Lippow, San Francisco, CA (US)
Assigned to Silver Creek Pharmaceuticals, Inc., San Francisco, CA (US)
Filed by Silver Creek Pharmaceuticals, Inc., San Francisco, CA (US)
Filed on Mar. 25, 2021, as Appl. No. 17/212,270.
Application 17/212,270 is a division of application No. 16/524,451, filed on Jul. 29, 2019, granted, now 10,988,547, issued on Apr. 27, 2021.
Application 14/967,980 is a division of application No. 13/068,808, filed on May 20, 2011, granted, now 9,238,080, issued on Jan. 19, 2016.
Application 16/524,451 is a continuation of application No. 15/618,478, filed on Jun. 9, 2017, granted, now 10,407,512, issued on Sep. 10, 2019.
Application 15/618,478 is a continuation of application No. 14/967,980, filed on Dec. 14, 2015, granted, now 9,718,892, issued on Aug. 1, 2017.
Claims priority of provisional application 61/347,040, filed on May 21, 2010.
Prior Publication US 2021/0214463 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 47/66 (2017.01); A61K 47/68 (2017.01); C07K 16/46 (2006.01); B82Y 5/00 (2011.01); C07K 14/475 (2006.01); C12N 15/62 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01); C07K 14/485 (2006.01); C07K 14/65 (2006.01); C07K 16/44 (2006.01)
CPC C07K 16/46 (2013.01) [A61K 45/06 (2013.01); A61K 47/66 (2017.08); A61K 47/6811 (2017.08); A61K 47/6891 (2017.08); B82Y 5/00 (2013.01); C07K 14/47 (2013.01); C07K 14/475 (2013.01); C07K 14/485 (2013.01); C07K 14/65 (2013.01); C07K 16/44 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/80 (2013.01)] 20 Claims
 
1. A method for treating kidney tissue undergoing necrosis or apoptosis, the method comprising: administering to a subject in need thereof a therapeutically effective amount of a bi-specific fusion protein comprising Annexin V comprising an amino acid sequence having at least 99% identity with SEQ ID NO: 31, and IGF-1 comprising an amino acid sequence having at least 98.5% identity with SEQ ID NO: 3, so as to maintain viability of healthy kidney tissue cells.